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1. INTRODUCTION {#jcmm15269-sec-0001}
===============

In all vertebrates, the RUNX family of transcriptional regulators containing the runt domain (RD) comprises three isoforms: RUNX1, RUNX2 and RUNX3 that, together with the non‐DNA‐binding CBFβ subunit, regulate many developmental processes.[^1^](#jcmm15269-bib-0001){ref-type="ref"}, [^2^](#jcmm15269-bib-0002){ref-type="ref"} The RUNX members specify their functions depending on their cellular and tissue expression: RUNX1 plays a key role in blood development, primarily in the haematopoietic stem cells (HSCs), RUNX2 is manly involved in bone morphogenesis, and RUNX3 in cell growth of neurons, epithelial cells and T cells. However, the three RUNX proteins could exert biological activities also in other organs[^3^](#jcmm15269-bib-0003){ref-type="ref"}, [^4^](#jcmm15269-bib-0004){ref-type="ref"}, [^5^](#jcmm15269-bib-0005){ref-type="ref"}; for example, RUNX2 and RUNX3 are known to play a role during haematopoiesis together with RUNX1. In addition, all the *RUNX* genes are transcribed by a distal and a proximal promoter (*P1* and *P2,* respectively) in two main isoforms that differ in the 5′UTR and in the coding sequence of the first exon.[^6^](#jcmm15269-bib-0006){ref-type="ref"}, [^7^](#jcmm15269-bib-0007){ref-type="ref"} The *P1* and *P2RUNX* transcripts are differentially expressed in diverse cell types and during specific developmental stages. Indeed, *P1* and *P2RUNX1* promoters have been reported to have specific activity patterns in the different haematopoietic lineages during development.[^8^](#jcmm15269-bib-0008){ref-type="ref"}

RUNX1 function during haematopoiesis is strictly regulated by post‐transcriptional and post‐translational modifications such as alternative splicing, acetylation, methylation, phosphorylation and ubiquitination.[^9^](#jcmm15269-bib-0009){ref-type="ref"} As transcription factor, RUNX1 targets multiple genes, many of which are also pivotal transcriptional regulators involved in the formation of all haematopoietic lineages including the haematopoietic‐specific member of E‐twenty‐six (ETS) family, PU.1.[^10^](#jcmm15269-bib-0010){ref-type="ref"}, [^11^](#jcmm15269-bib-0011){ref-type="ref"} Furthermore, the activity of RUNX1 is carried out by its interaction with different proteins fundamental during haematopoiesis such as GATA1, PU.1, CEBPA, PAX5 and ETS1.[^10^](#jcmm15269-bib-0010){ref-type="ref"}, [^12^](#jcmm15269-bib-0012){ref-type="ref"}, [^13^](#jcmm15269-bib-0013){ref-type="ref"}, [^14^](#jcmm15269-bib-0014){ref-type="ref"}

Given the high complexity in RUNX1 expression and function, its deregulation is commonly associated with haematopoietic diseases. Depletion of *Runx1* in mice and zebrafish models leads to severe defects or complete absence of definitive haematopoiesis.[^15^](#jcmm15269-bib-0015){ref-type="ref"}, [^16^](#jcmm15269-bib-0016){ref-type="ref"}, [^17^](#jcmm15269-bib-0017){ref-type="ref"}, [^18^](#jcmm15269-bib-0018){ref-type="ref"} *RUNX1* is frequently involved in chromosomal translocations observed in acute leukaemias, such as ETV6‐RUNX1 in t(12;21) and RUNX1‐EVI1 in t(3;21),[^19^](#jcmm15269-bib-0019){ref-type="ref"} while the formation of the chimeric protein RUNX1‐CBF2T1 (AML1‐ETO) is associated with the M2 subtype of acute myeloid leukaemia (AML).[^20^](#jcmm15269-bib-0020){ref-type="ref"}, [^21^](#jcmm15269-bib-0021){ref-type="ref"} *RUNX1* mutations determine the familial platelet disorder with a propensity for AML (AML/FPD) and the minimally differentiated acute myeloid leukaemia (AML/M0).[^22^](#jcmm15269-bib-0022){ref-type="ref"} Importantly, regulation of *RUNX1* dosage is essential for the maintenance of normal haematopoiesis[^23^](#jcmm15269-bib-0023){ref-type="ref"} and several haematopoietic transcription factors are deputed to regulate *RUNX1* expression such as Gata2, Ets factors (Fli‐1, Elf‐1 and Pu.1) and the SCL/Lmo2/Ldb1 complex.[^24^](#jcmm15269-bib-0024){ref-type="ref"} In zebrafish, the subunit Rad21 of the cohesin complex has been identified as a regulator of *runx1* through a forward genetic screen,[^25^](#jcmm15269-bib-0025){ref-type="ref"} and multiple predicted and in vivo validated binding sites of Rad21 have been shown to be involved in the regulation of the zebrafish *runx1*.[^26^](#jcmm15269-bib-0026){ref-type="ref"}

In this work, we demonstrate that NIPBL, another member of the cohesin complex, positively regulates *RUNX1* expression in two different contexts in which it exerts important functions: normal cord blood megakaryocytes derived from healthy donors and bone marrow samples derived from adult AML patients. In addition, we generate a zebrafish model in which the *nipblb*‐mediated dysregulation of *runx1* expression leads to haematopoietic defects resulting in decreased expression of the erythroid marker *gata1a* and reduction of mature circulating erythrocytes, and increased expression of myeloid precursors positive for the *spi1b* marker. Our data confirm the regulatory loop between RUNX1‐GATA1 and PU.1 during haematopoiesis and highlight a new role of NIPBL on top of this route.

2. MATERIALS AND METHODS {#jcmm15269-sec-0002}
========================

2.1. Patients {#jcmm15269-sec-0003}
-------------

Diagnostic bone marrow samples from 34 adult patients affected by AML were collected and characterized for specific molecular aberrancies, including translocations t(9;22), t(8;21) and inv(16), in accordance with specific clinical protocol requirements. The analysed patients belong to different French‐American‐British (FAB) classification systems (FABs), excluding M3; therefore, all patients were negative for translocation t(15;17) (Table [1](#jcmm15269-tbl-0001){ref-type="table"}). Bone marrow of healthy individuals was collected as controls for gene expression assays, upon appropriate informed consent ASG‐A‐052A approved on 8 May 2012 by Azienda Socio‐Sanitaria of Monza (ASST‐Monza). Human material and derived data were used in accordance with the Declaration of Helsinki.

###### 

Clinical Features of patients\' cohort

  Age at onset   Karyotype   FAB classification                                   NPM     FLT3‐ITD   t(9;22)                 t(8;21)   inv(16)   
  -------------- ----------- ---------------------------------------------------- ------- ---------- ----------------------- --------- --------- -----
  1              47          46,XX,t(10;11)(p11;p15)\[20\]                        M0      NEG        NEG                     NEG       NEG       NEG
  2              49          46,XY\[20\]                                          M0/M1   NEG        NEG                     NEG       NEG       NEG
  3              48          46,XX\[20\]                                          M1      NEG        NEG                     NEG       NEG       NEG
  4              72          47,XY,+mar\[10\]/46,XY\[10\]                         M2      NEG        NEG                     NEG       NEG       NEG
  5              58          46,XX,t(3;5)(q25;q34)\[20\]                          M2      NEG        NEG                     NEG       NEG       NEG
  6              59          46,XY\[20\]                                                  NEG        POS                     NEG       NEG       NEG
  7              33          46,XY\[15\]                                          M1      NEG        POS                     NEG       NEG       NEG
  8              30          46,XY\[20\]                                          M5      NEG        POS                     nk        NEG       NEG
  9              58          46,XY,inv(16)(p13q22)\[20\]                          M4      NEG        POS                     nk        NEG       POS
  10             76          nk                                                   M5      NEG        POS                     nk        NEG       NEG
  11             78          46,XX\[27\]                                          M4      NEG        POS                     nk        NEG       NEG
  12             53          46,XY\[22\]                                          M4      NEG        POS                     nk        NEG       NEG
  13             64          46,XX\[20\]                                          M5      NEG        POS                     nk        NEG       NEG
  14             75          46,XY\[26\]                                          M4      NEG        POS                     nk        NEG       NEG
  15             39          46,XY\[20\]                                          M1      POS (A)    NEG                     NEG       NEG       NEG
  16             47          46,XX\[20\]                                          M5      POS (A)    NEG                     NEG       NEG       NEG
  17             63          46,XY,t(8;14)(q24;q32),add(13q34)\[18\]/46,XY\[9\]   nk      POS (D)    NEG                     nk        NEG       NEG
  18             58          46,XY/47,XY,+8\[7/10\]                               nk      POS (QM)   NEG                     nk        NEG       NEG
  19             50          46,XX\[20\]                                          M4      POS (A)    NEG                     nk        NEG       NEG
  20             77          46,XY\[20\]                                          nk      POS (A)    NEG                     nk        NEG       NEG
  21             54          46,XX,t(9;22)(q34;q11)\[14\]/46,XX\[6\]              M4      POS (A)    NEG                     POS       NEG       NEG
  22             60          46,XX\[6\]                                           nk      POS        NEG                     nk        NEG       NEG
  23             62          46,XX\[25\]                                          M5      POS (A)    NEG ITD/POS D835/D836   nk        NEG       NEG
  24             58          46,XX\[20\]                                          nk      POS (A)    NEG                     nk        NEG       NEG
  25             48          46,XX\[20\]                                          M4      POS (A)    POS                     NEG       NEG       NEG
  26             51          46,XX\[20\]                                          M5      POS (A)    POS                     NEG       NEG       NEG
  27             68          46,XX\[20\]                                          M4      POS (A)    POS ITD/POS D835/D836   NEG       NEG       NEG
  28             46          46,XY\[20\]                                          M2      POS        POS                     NEG       NEG       NEG
  29             39          46,XX\[22\]                                          M1      POS (A)    POS                     nk        NEG       NEG
  30             58          46,XY                                                M5      POS (A)    POS                     nk        NEG       NEG
  31             35          46,XY,?r(18)(?)\[16\]/47,idem,+8\[3\]/46,XY\[1\]     nk      POS (B)    POS                     nk        NEG       NEG
  32             58          46,XY\[24\]                                          M1      POS (A)    POS                     nk        NEG       NEG
  33             70          46,XY\[20\]                                          M5      POS (A)    POS                     nk        NEG       NEG
  34             12          46,XY\[24\]                                          nk      POS (A)    POS                     NEG       NEG       NEG

John Wiley & Sons, Ltd

2.2. Animals {#jcmm15269-sec-0004}
------------

Zebrafish embryos were raised and maintained according to international (European Union Directive 2010/63/EU) and national (Italian decree no. 26 of 4 March 2014) guidelines on the protection of animals used for scientific purposes. The fish were maintained under standard conditions in the fish facilities of Bioscience Dept, University of Milan, Via Celoria 26‐20133 Milan, Italy (Aut. Prot, n. 295/2012‐A---20 December 2012). We express the embryonic ages in hours post‐fertilization (hpf) and days post‐fertilization (dpf). Zebrafish AB strains obtained from the Wilson laboratory (University College London, London, UK) and *Tg(fli1a:EGFP)^y1 ^* [^27^](#jcmm15269-bib-0027){ref-type="ref"} were maintained at 28°C on a 14‐h light/10‐h dark cycle. Embryos were collected by natural spawning, staged according to Ref. [28](#jcmm15269-bib-0028){ref-type="ref"} and raised at 28°C in fish water (Instant Ocean, 0,1% Methylene Blue) in Petri dishes, according to established techniques. To prevent pigmentation, 0,003% 1‐phenyl‐2‐thiourea (PTU, Sigma‐Aldrich) was added to the fish water prior to 24 hpf. Before observations and picture acquisitions, embryos were washed, dechorionated and anaesthetized, with 0.016% tricaine (ethyl 3‐aminobenzoate methanesulfonate salt; Sigma‐Aldrich).

2.3. Reverse transcription and real‐time quantitative polymerase chain reaction assays (RT‐qPCR) {#jcmm15269-sec-0005}
------------------------------------------------------------------------------------------------

RNA was extracted from human and zebrafish embryos using TRIzol reagents (Life Technologies), following the manufacturer\'s protocol. For human samples and RT‐qPCR experiments, Superscript II enzyme (Life Technologies) was used for cDNA synthesis. For this set of experiments, a LightCycler 480II (Roche Diagnostics, Basel, Swiss) was used. Probes were selected according to the Software Probe Finder (Roche Diagnostics) and are reported in Table [2](#jcmm15269-tbl-0002){ref-type="table"}. *hGUS* gene was used as reference gene in human patients and cells derived from healthy donors as standard control. For zebrafish samples, DNase I RNase‐free (Roche Diagnostics) treatment was performed to avoid possible genomic contamination and 1 μg of RNA was reverse‐transcribed using the "ImProm‐II™ Reverse Transcription System" (Promega). RT‐qPCRs were carried out in a total volume of 20 μl containing 1X iQ SYBR Green Supermix (Promega), using proper amount of the RT reaction and a mixture of oligo(dT) and random primers according to manufacturer\'s instructions. RT‐qPCRs were performed using the Bio‐Rad iCycler iQ Real‐Time Detection System (Bio‐Rad). For normalization purposes, *rpl8* expression levels were tested in parallel with the gene of interest. Primers are reported in Table [3](#jcmm15269-tbl-0003){ref-type="table"}. Expression levels in the Y‐axis were relative to the control.

###### 

Human primer sequences and probe numbers used in qPCR experiments

  PRIMER     length   sequence                   PROBE
  ---------- -------- -------------------------- -------
  hGUS‐L     20       CGCCCTGCCTATCTGTATTC       57
  hGUS‐R     20       TCCCCACAGGGAGTGTGTAG        
  hNIPBL‐L   19       CTATGCGAACAGCCCAAAA        55
  hNIPBL‐R   24       TTCACCTTGCTTACTACCACATTT    
  hRAD21‐L   20       ATTGACCCAGAGCCTGTGAT       62
  hRAD21‐R   20       GGGGAAGCTCTACAGGTGGT        
  HRUNX1‐L   18       ACAAACCCACCGCAAGTC         21
  HRUNX1‐R   23       CATCTAGTTTCTGCCGATGTCTT     
  HSPI1‐L    20       CTGGAGTTCCCCAATCACAT       25
  HSPI1‐R    23       TGATTTCAGACATGACAAAAGGA     

John Wiley & Sons, Ltd

###### 

Zebrafish primer sequences used in qPCR experiments

  PRIMER            Length   Sequence
  ----------------- -------- ----------------------------
  zrpl8‐L           21       CTCCGTCTTCAAAGACCATGT
  zrpl8‐R           21       TCCTTCACGATCCCCTTGATG
  zP1‐runx1‐L       20       ATGGCCTCCAACAGCATCTT
  zP2‐runx1‐L       20       GAGCCGAAACTCACGGAGAC
  zrunx1 common‐R   20       GCAAACCCTCGCTCATCTTC
  zspi1b‐L          19       GCCATTTCATGGACCCAGG
  zspi1b‐R          19       ACACCGATGTCCGGGGCAA
  zgata1a‐L         26       AACGACATCTTCAATACTACACTTGC
  zgata1a‐R         18       GGACACCCAACGAGAAGG

John Wiley & Sons, Ltd

2.4. In situ hybridization, *o*‐dianisidine and immunofluorescence analyses {#jcmm15269-sec-0006}
---------------------------------------------------------------------------

Whole‐mount in situ hybridization (WISH) experiments were carried out as described by Thisse et al.[^29^](#jcmm15269-bib-0029){ref-type="ref"} For quantification of the observed phenotypes, WISH experiments were done at least in 3 independent batches of embryos (minimum 15‐20 embryos for each category). Embryos were fixed overnight in 4% paraformaldehyde (PFA, Sigma‐Aldrich) in phosphate‐buffered saline (PBS) at 4°C, and then dehydrated stepwise to methanol and stored at −20°C. Antisense riboprobes were previously in vitro labelled with modified nucleotides (*i.e.* digoxigenin, Roche Diagnostics). *runx1*,[^30^](#jcmm15269-bib-0030){ref-type="ref"} *spi1b* [^31^](#jcmm15269-bib-0031){ref-type="ref"} and *gata1a* [^32^](#jcmm15269-bib-0032){ref-type="ref"} probes were synthesized according to literature. To detect haemoglobin activity, *o*‐dianisidine (Sigma) staining was performed as described in Ref. [33](#jcmm15269-bib-0033){ref-type="ref"}. Controls and MO‐injected embryos at the same developmental stage were scored from 1 to 3 according to the intensity of the staining by microscopy, and *o*‐dianisidine‐positive cells on the yolk surface and in the Caudal haematopoietic tissue (CHT) were compared.

2.5. Injections {#jcmm15269-sec-0007}
---------------

Injections were carried out on one‐ to two‐cell stage embryos. Details of concentration and sequence of *nipblb* morpholino (*nipblb*‐MO, Gene Tools, Oregon, US) and *rad21*‐MO (Gene Tools) are described in Ref. [^34^](#jcmm15269-bib-0034){ref-type="ref"} and Ref. [^25^](#jcmm15269-bib-0025){ref-type="ref"}, respectively. In all experiments, MO‐injected embryos were compared to embryos at the same developmental stage injected with the same amount of a ctrl‐MO that has no target in zebrafish (Gene Tools LLC). The *runx1/*PCS2+ construct was kindly provided by C.E. Burns[^18^](#jcmm15269-bib-0018){ref-type="ref"} and injected at a concentration of 200 pg/embryo.

2.6. Statistical analyses {#jcmm15269-sec-0008}
-------------------------

For RT‐qPCR experiments, data were statistically analysed applying one‐way analysis of variance (ANOVA), defining *P* ≤ .05 (\*), *P* ≤ .01 (\*\*) and *P* ≤ .001 (\*\*\*) as statistically significant values.[^35^](#jcmm15269-bib-0035){ref-type="ref"} Data were analysed using the comparative ΔΔCt method. Both ANOVA and standard deviation (SD) values refer to data from triplicate samples. In zebrafish, at least three different experiments were done for each analysis.

The degree of linear relationship between *RAD21*, *NIPBL*, *RUNX1, MPL* and *SPI1* expression levels was calculated using Spearman\'s correlation coefficient (r value).

2.7. TRAM analysis {#jcmm15269-sec-0009}
------------------

TRAM (Transcriptome Mapper) software[^36^](#jcmm15269-bib-0036){ref-type="ref"} allows the import, decoding of probe set identifiers to gene symbols via UniGene data parsing,[^37^](#jcmm15269-bib-0037){ref-type="ref"} integration and normalization of gene expression data in tab‐delimited text format for the generation and analysis of transcriptome maps. We analysed the transcriptome map previously obtained from a gene expression profile datasets for normal human megakaryocytes (MK) cells derived from healthy donors.[^38^](#jcmm15269-bib-0038){ref-type="ref"} The dataset is composed of 19 samples previously described (Pool D in Ref. [^38^](#jcmm15269-bib-0038){ref-type="ref"}). In particular, we used the function \"Export\" of TRAM software in order to obtain normalized expression values assigned to *NIPBL*, *RAD21*, *RUNX1* and *MPL* genes for each sample. The degree of linear relationship between *RAD21*, *NIPBL*, *RUNX1*, *MPL* and *SPI1* expression levels was calculated using Spearman\'s correlation coefficient (r value).

3. RESULTS {#jcmm15269-sec-0010}
==========

3.1. Positive correlation between *NIPBL* and *RUNX1* expression in normal megakaryocytes derived from healthy donors and bone marrow cells derived from adult AML patients {#jcmm15269-sec-0011}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*RUNX1* expression has been reported to be regulated by the cohesin subunit RAD21 and the CTCF insulator in human myelocytic leukaemia cells HL‐60.[^26^](#jcmm15269-bib-0026){ref-type="ref"} As RUNX1 is pivotal in the differentiation of megakaryocytes and myeloid lineages, we investigated the relative expression of *RAD21* and *RUNX1* in two different contexts in which *RUNX1* exerts important functions: the differentiation of the megakaryocytes and myeloid compartments under physiological and pathological conditions. For the megakaryocytes compartment in physiological condition, we performed in silico analyses of quantitative transcriptome maps, using TRAM (Transcriptome Mapper) software, which allows import and effective integration of data obtained by different experimenters, experimental platforms and data sources.[^36^](#jcmm15269-bib-0036){ref-type="ref"} In megakaryocytes (MK) derived from healthy donors, *RAD21* expression did not correlate with the expression levels of *RUNX1* (Figure [1A](#jcmm15269-fig-0001){ref-type="fig"})*.* Conversely, we found a positive correlation between the expression of *RUNX1* and that of *NIPBL*, another member of the cohesin complex (Figure [1B](#jcmm15269-fig-0001){ref-type="fig"}). To explore the myeloid compartment under pathological condition, we used bone marrow (BM) cells derived from adult AML patients. Similar to TRAM analyses, when *RAD21* and *RUNX1* expressions were investigated in a cohort of 34 AML adult patients without anomalies in chromosome 21 that contains the *RUNX1* locus, no significant correlation was reported (Figure [1C](#jcmm15269-fig-0001){ref-type="fig"}). Conversely, we observed the positive *NIPBL/RUNX1* correlation already detected in megakaryocytes (Figure [1D](#jcmm15269-fig-0001){ref-type="fig"}).

![Positive correlation between *NIPBL* and *RUNX1* expression in megakaryocytes derived from healthy donors and in bone marrow cells derived from 34 adult AML patients. A and B, Spearman\'s correlation between *RUNX1* and *RAD21* (A) or *NIPBL* (B) in cord blood megakaryocytes (MK) derived from healthy donors. C and D, Spearman\'s correlation between *RUNX1* and *RAD21* (C) or *NIPBL* (D) in bone marrow cells (BM) derived from 34 adult AML patients without aberrant *RUNX1* alterations (mutations or translocations). E and F, Spearman\'s correlation between *RUNX1* and *NIPBL* in 34 adult AML patients without (NPM1wt) (E) or with NPM1 mutation (NPMc+) (F). Spearman\'s correlation analysis showed a significant positive correlation of the ratio of *RUNX1* expression only versus *NIPBL*, not versus *RAD21,*. *r* = Spearman\'s correlation coefficient](JCMM-24-6272-g001){#jcmm15269-fig-0001}

We previously showed that *NIPBL* transcript abundance is decreased in AML patients carrying the mutated *NUCLEOPHOSMIN1 (NPM1)*, which transfers NPM1 in the cytoplasm (NPMc+), compared to the NPM1 wild‐type (NPM1wt).[^34^](#jcmm15269-bib-0034){ref-type="ref"} Therefore, we analysed the correlation between the expression of *NIPBL* and *RUNX1* in BM cells derived from 20 patients NPMc+, selected among the 34 AML patients, compared to 14 patients NPM1wt and found a significant positive correlation in NPMc+ but not in NPM1wt AML patients (Figure [1E‐F](#jcmm15269-fig-0001){ref-type="fig"}). Taken together, these findings suggest a new role for NIPBL, different from that of RAD21, in the regulation of *RUNX1* expression and that aberrant expression of *NIPBL,* such as in AML patients with NPM+ mutation, might lead to alteration in *RUNX1* transcript levels.

3.2. Knock‐down of *nipblb* specifically reduces *runx1* expression in zebrafish {#jcmm15269-sec-0012}
--------------------------------------------------------------------------------

To confirm the positive correlation between *NIPBL* and *RUNX1* observed in human, we took advantage of a zebrafish model with down‐regulation of *nipblb*, the orthologue of the human *NIPBL*, previously generated in our laboratory.[^34^](#jcmm15269-bib-0034){ref-type="ref"} The expression of *runx1* was analysed in embryos at 30 and 48 hpf as definitive HSCs arise from the vascular endothelium from these developmental stages. Moreover, we verified that both *P1*‐*P2runx1* isoforms were highly expressed from 24 hpf (Figure [S1](#jcmm15269-sup-0001-FigS1-S2){ref-type="supplementary-material"}). WISH analyses showed a reduction of the *runx1* transcript in the aorta‐gonad mesonephric (AGM) tissue in *nipblb*‐MO‐injected embryos compared to controls at the same developmental stage. The injection of the full‐length *runx1*/mRNA rescued this phenotype as expected (Figure [2A‐C](#jcmm15269-fig-0002){ref-type="fig"}). As the full‐length *runx1* riboprobe does not distinguish between the *P1*‐ and *P2runx1* isoforms present in zebrafish,[^8^](#jcmm15269-bib-0008){ref-type="ref"} we performed RT‐qPCR analysis of both isoforms, revealing a significant reduction exclusively in *P2runx1* transcript levels following *nipblb* down‐regulation*.* The expression of both isoforms was increased in embryos injected with *nipblb*‐MO and *runx1*mRNA, confirming the efficacy of the *runx1* overexpression (Figure [2D‐E](#jcmm15269-fig-0002){ref-type="fig"}). These results provide evidence that *nipblb* knock‐down causes the reduction of *runx1* in zebrafish, confirming the positive correlation between *NIPBL* and *RUNX1* expression observed in normal megakaryocytes and in BM of  AML patients.

![*runx1* expression is specifically reduced following *nipblb* down‐regulation. A‐C WISH analyses of *runx1* expression at the stage of 30 hpf in embryos injected with control morpholino (ctrl‐MO*)* (A), *nipblb*‐MO (B) and *nipblb*‐MO with *runx1*‐mRNA (C)*.* The *runx1* expression in the caudal region (higher magnification in the box) is reduced following *nipblb* down‐regulation and rescued in embryos co‐injected with *nipblb*‐MO and *runx1* mRNA. E‐F, RT‐qPCR analyses of the *P1runx1* (D) and *P2runx1* (E) isoforms in ctrl‐MO‐, *nipblb*‐MO‐ and *nipblb*‐MO/*runx1*mRNA‐injected embryos at 48 hpf. Scale bars indicate 100 μm. One‐way ANOVA with Bonferroni correction, ^\*\*^ *P* \< .01, ^\*^ *P* \< .05, n.s: non‐significant](JCMM-24-6272-g002){#jcmm15269-fig-0002}

3.3. NIPBL‐mediated RUNX1 down‐regulation impairs the expression of RUNX1 target genes {#jcmm15269-sec-0013}
--------------------------------------------------------------------------------------

We further verified whether the NIPBL‐mediated RUNX1 reduction affects the expression of *RUNX1* haematopoietic downstream targets*.* In MK cells derived from healthy donors, we observed a positive correlation between the expression of *RUNX1* and that of *MPL* gene, the marker of megakaryocyte/platelet differentiation (Figure [3A](#jcmm15269-fig-0003){ref-type="fig"}).[^39^](#jcmm15269-bib-0039){ref-type="ref"} In BM cells derived from AML human patients, we showed a positive correlation between the expression of *RUNX1* and its targets *SPI1*, the marker of myeloid precursors (Figure [3B](#jcmm15269-fig-0003){ref-type="fig"}).[^40^](#jcmm15269-bib-0040){ref-type="ref"} The expression of *runx1* targets *gata1a* and *spi1b* was investigated also in zebrafish in *nipblb*‐MO‐injected embryos and controls at 48 hpf. The expression of *gata1a*, analysed by RT‐qPCR, was significantly decreased following *nipblb* down‐regulation as a result of *runx1* reduction. Indeed, the injection of the *runx1*mRNA in the *nipblb*‐MO‐injected embryos rescued the *gata1a* expression (Figure [3C](#jcmm15269-fig-0003){ref-type="fig"}). Conversely, the expression of *spi1b* was significantly increased in both *nipblb*‐MO‐ and *nipblb*‐MO/*runx1*mRNA‐injected embryos (Figure [3D](#jcmm15269-fig-0003){ref-type="fig"}). Consistent with the role of *runx1* in the positive regulation of the erythroid lineage, mature circulating erythrocytes, visualized by *o*‐dianisidine staining at 48 hpf, were drastically reduced in *nipblb*‐MO‐injected embryos (70%; N = 140), compared to controls (Figure [3E‐F](#jcmm15269-fig-0003){ref-type="fig"}). This phenotype is not caused by alterations in vascular tree development as shown in the *Tg(fli1a:EGFP)^y1^* embryos (Figure [S2](#jcmm15269-sup-0001-FigS1-S2){ref-type="supplementary-material"}), or absence of blood flow (data not shown). The reduction of *o*‐dianisidine‐positive erythrocytes was rescued in the 75% of the *nipblb*‐MO‐*runx1*mRNA‐injected embryos (N = 113) (Figure [3G](#jcmm15269-fig-0003){ref-type="fig"}), confirming that the phenotype is dependent on *nipblb*‐mediated *runx1* reduction.

![NIPBL‐mediated RUNX1 down‐regulation leads to impaired expression of RUNX1 target genes in both human and zebrafish. A, Spearman\'s correlation between *RUNX1* and *MPL* in cord blood megakaryocytes (MK) derived from healthy donors. B, Spearman\'s correlation between *RUNX1* and *SPI1* in bone marrow cells (BM) derived from 34 adult AML patients without aberrant *RUNX1* alterations (mutations or translocations). *r* = Spearman\'s correlation coefficient. C and D, RT‐qPCR analyses of 48 hpf ctrl‐, *nipblb‐* and *nipblb‐*MO/*runx1*mRNA‐injected embryos. C, The expression of the erythroid marker *gata1a* was decreased following *nipblb‐*MO injection in comparison with controls and rescued in *nipblb*‐MO/*runx1*mRNA‐injected embryos. D, The expression of the myeloid marker *spi1b* was increased in both *nipblb‐*MO‐ and *nipblb*‐MO/*runx1*mRNA‐injected embryos in comparison with controls. E‐G, *O*‐dianisidine staining showed a reduction of mature circulating erythrocytes in *nipblb*‐MO‐injected embryos at 48 hpf in comparison with ctrl‐MO. Co‐injection with the full‐length *runx1* mRNA rescues the *o*‐dianisidine reduction. Lateral views anterior to the left (upper panels) and ventral views of the anterior region (lower panels). H‐J, WISH analyses showed an increased expression of *spi1b* in *nipblb*‐MO‐ and *nipblb*‐MO/*runx1*mRNA‐injected embryos in comparison with ctrl‐MO. Scale bars indicate 100 μm in (E‐G) and 200 in μm in (H‐J)*.* One‐way ANOVA with Bonferroni correction, ^\*\*\*^P \< .001 ^\*\*^ *P* \< .01, ^\*^ *P* \< .05, n.s: non‐significant](JCMM-24-6272-g003){#jcmm15269-fig-0003}

WISH analyses of *spi1b* expression showed the increase of the transcript in the CHT of *nipblb*‐MO‐injected embryos (Figure [3H‐I](#jcmm15269-fig-0003){ref-type="fig"}) confirming the RT‐qPCR data and our previous findings.[^34^](#jcmm15269-bib-0034){ref-type="ref"} In agreement with the positive regulation exerted by *runx1* on *spi1b*, the injection of the *runx1*/mRNA further enhanced this phenotype (Figure [3J](#jcmm15269-fig-0003){ref-type="fig"}).[^40^](#jcmm15269-bib-0040){ref-type="ref"}

As it has been previously demonstrated that *rad21*, another member of the cohesin complex, regulates *runx1* in zebrafish embryos during primitive haematopoiesis,[^25^](#jcmm15269-bib-0025){ref-type="ref"}, [^26^](#jcmm15269-bib-0026){ref-type="ref"} we further verified the expression of *runx1* during definitive haematopoiesis following *rad21* down‐regulation by means of morpholino injection.[^25^](#jcmm15269-bib-0025){ref-type="ref"} *rad21*‐MO‐injected embryos at 48 hpf showed an increased expression of both *P1* and *P2runx1* isoforms and a consequent increase in the expression of the *runx1* downstream targets *gata1a* and *spi1b* (Figure [4A‐D](#jcmm15269-fig-0004){ref-type="fig"}). These data are in agreement with the negative regulation exerted by *RAD21* on *RUNX1* expression reported in the myeloid HL60 cell line.[^26^](#jcmm15269-bib-0026){ref-type="ref"}

![The down‐regulation of *rad21* in zebrafish enhances the expression of *runx1* and its downstream targets *gata1a* and *spi1b*. A‐D, RT‐qPCR analyses of 48 hpf ctrl‐ and *rad21‐*MO‐injected embryos. The expression of both *P1* (A) and *P2runx1* (B) isoforms and of *runx1* targets *gata1a* (C) and *spi1b* (D) was increased following *rad21‐*MO injection in comparison to  controls at 48 hpf*.* One‐way ANOVA with Bonferroni correction, ^\*\*\*^ *P* \< .001, ^\*\*^P \< .01, ^\*^ *P* \< .05, n.s: non‐significant](JCMM-24-6272-g004){#jcmm15269-fig-0004}

4. DISCUSSION {#jcmm15269-sec-0014}
=============

The transcription factor *RUNX1* is a pivotal gene in the development and differentiation of HSCs: as transcription factor, it controls the expression of master genes involved in megakaryocytes and myeloid lineages differentiation*,* and it interacts with different proteins fundamental during haematopoiesis. Somatic translocations and mutations of *RUNX1* are causative of haematological diseases such as myelodysplastic syndrome, acute myeloid leukaemia, acute lymphoblastic leukaemia, chronic myelomonocytic leukaemia and acute megakaryoblastic leukaemia with familial platelet disorder. In addition, dysregulation of *RUNX1* expression might lead to impaired haematopoiesis and the insurgence of a pathological condition. Among the genes discovered to regulate *RUNX1*, there is *RAD21*, a member of the cohesin complex, and the *CTCF* insulator.[^26^](#jcmm15269-bib-0026){ref-type="ref"} In human K562 cells and murine and zebrafish models, RAD21 and CTCF bind to a cis‐regulatory element (CRE) enhancer located in an intron between the *P1* and *P2RUNX1* promoters, associated with RNApolII.[^41^](#jcmm15269-bib-0041){ref-type="ref"} As cohesins preferentially bind to transcriptionally active genes and recruit RNAPolII and chromatin modifiers to activate gene transcription,[^42^](#jcmm15269-bib-0042){ref-type="ref"} it would have been expected that RAD21 positively regulates *RUNX1* transcription by binding to the CRE between *P1* and *P2* promoters. This finding is reported by Supernat and colleagues [^43^](#jcmm15269-bib-0043){ref-type="ref"} in patients with endometrial cancers. However, in a zebrafish mutant for Rad21 the expression of *runx1* was reduced [^25^](#jcmm15269-bib-0025){ref-type="ref"} and the *P1* and *P2runx1* isoforms were differently expressed: *P1* isoform was increased, while *P2* was not varied or even decreased following Rad21 depletion.[^26^](#jcmm15269-bib-0026){ref-type="ref"} Moreover, the silencing of *RAD21* in the human HL60 leukaemic cell line leads to an enhanced expression of *RUNX1* indicating that RAD21 might also repress *RUNX1* expression.[^26^](#jcmm15269-bib-0026){ref-type="ref"} In our study, we did not observe a significant correlation between the expression of *RAD21* and *RUNX1* neither in megakaryocytes derived from healthy donors, nor in bone marrow cells derived from a selected cohort of adult AML patients. However, we showed that during definitive haematopoiesis, the down‐regulation of *rad21* in zebrafish enhances the expression of both *P1* and *P2runx1* isoforms leading to impaired expression of the *runx1* downstream targets *gata1a* and *spi1b*.

The different members of the cohesin complex can exert similar or individual functions in the regulation of gene expression. For example, Zuin et al[^44^](#jcmm15269-bib-0044){ref-type="ref"} demonstrated that *NIPBL* binds to chromatin independently in time and space than other cohesins, revealing a new role for NIPBL as transcriptional regulator not linked to the cohesin complex. In this work, we demonstrate that NIPBL exerts a different regulation on *RUNX1* expression than RAD21. Indeed, in three different contexts: normal megakaryocytes derived from healthy donors, bone marrow cells derived from adult AML patients and zebrafish embryos with *nipblb* down‐regulation, we demonstrate a positive correlation between *NIPBL* and *RUNX1* expression.

The NIPBL‐mediated RUNX1 dysregulation affects the RUNX1 downstream targets responsible for the differentiation of the erythroid and myeloid lineages. *RUNX1* augmented GATA1‐mediated promoter activation; in this regard, the decrease in *RUNX1* transcription/activity leads to down‐regulation of the erythroid *GATA1* transcription factor.[^45^](#jcmm15269-bib-0045){ref-type="ref"} Interestingly, cohesins‐haploinsufficient cells presented enriched or depleted *GATA1* consensus binding sites indicating that they can modulate *GATA1* activity directly or through other molecules.[^12^](#jcmm15269-bib-0012){ref-type="ref"}, [^46^](#jcmm15269-bib-0046){ref-type="ref"}

Also the *SPI* expression is positively regulated by RUNX1, facilitating the interaction between the *SPI* enhancer and its proximal promoter.[^47^](#jcmm15269-bib-0047){ref-type="ref"} Indeed, we observed a positive correlation between *RUNX1* and *SPI1* in human samples and in zebrafish when we forced *runx1* expression. However, following *nipblb* down‐regulation, we also observed an increase in *spi1b* expression according to our previous data.[^34^](#jcmm15269-bib-0034){ref-type="ref"} This result does not correlate with the *runx1* reduction and its positive activity on *spi1b* expression and raises three possibilities: first that the increased number of myeloid precursors, previously reported in zebrafish following *nipblb*‐MO injection,[^34^](#jcmm15269-bib-0034){ref-type="ref"} leads to an augmented number of cells expressing *spi1b* with a consequent total increase of *spi1b* transcript. Second, it has been reported that the chromatin structure at the *spi1b*/PU.1 locus could be differentially regulated during the different stages of haematopoiesis,[^11^](#jcmm15269-bib-0011){ref-type="ref"} suggesting the possibility that other mechanisms than RUNX1 might control *spi1b* expression. For example, we demonstrated that the canonical Wnt pathway, modulated by *nipblb*, has a pivotal role in regulating *spi1b* myeloid expression during definitive haematopoiesis in zebrafish.[^34^](#jcmm15269-bib-0034){ref-type="ref"} Moreover, in vitro and in vivo studies demonstrated that forced expression of *gata1* down‐regulates *spi1b*, while forced expression of *spi1b* down‐regulates *gata1*.[^48^](#jcmm15269-bib-0048){ref-type="ref"}, [^49^](#jcmm15269-bib-0049){ref-type="ref"}, [^50^](#jcmm15269-bib-0050){ref-type="ref"} In this scenario, the *nipblb*‐mediated *runx1* down‐regulation might lead to *spi1b* enforced expression that, in turn, reduces *gata1a* expression. Alternatively, the two *P1* and *P2runx1* isoforms might exert different functions on *spi1b* regulation. Indeed, as for the case of Rad21 zebrafish mutants,[^26^](#jcmm15269-bib-0026){ref-type="ref"} we demonstrated that the down‐regulation of *nipblb* differently affects the two isoforms by significantly reducing only the *P2runx1*. Third, it has been demonstrated that NIPBL might regulate SPI1 by itself, encompassing the Runx1 regulation.[^44^](#jcmm15269-bib-0044){ref-type="ref"}

Although in this work we did not address the mechanism through which NIPBL regulates *RUNX1* expression, we demonstrated that NIPBL positively regulates *RUNX1* transcription and that the link between *NIPBL* dysregulation and *RUNX1*‐driven haematopoietic defects might  explain haematological malignancy occurrence. Thus, also in the absence of *RUNX1* translocation or mutations, additional factors such as defects in the expression of *NIPBL* observed in AML patients might contribute to haematological diseases.
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